FindTrial
Sign In

The efficacy and safety of 2.5% testosterone gel for late-onset hypogonadsism patients evaluated by using salivary testosterone.

The efficacy and safety of 2.5% testosterone gel for late-onset hypogonadsism patients evaluated by using salivary testosterone. - The efficacy of 2.5% testosterone gel for late-onset hypogonadsism patients

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001011
Enrollment
15
Registered
2008-02-10
Start date
2008-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late-onset hypogonadism

Interventions

Examination of the circadian change and the highest time point of salivary testosterone levels after using testosterone gel. Subjects are provided with plastic sterile screw sputum processors to col

Sponsors

Teikyo University, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Late-onst hypogonadism patients at the age of 40to 80.

Exclusion criteria

Exclusion criteria: Patients having serious heart, iver, and renal dysfunction. Pasients who have serious pshychiatric problems are also excluded.

Design outcomes

Primary

MeasureTime frame
Serum hormone profiles,salivary testosterone, AMS score.—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026